Ratings HealthStream, Inc.

Equities

HSTM

US42222N1037

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
25.61 ^USD	-1.20%		+3.10%	-5.25%

Apr. 23	Transcript : HealthStream, Inc., Q1 2024 Earnings Call, Apr 23, 2024
Apr. 22	Earnings Flash (HSTM) HEALTHSTREAM Posts Q1 Revenue $72.8M, vs. Street Est of $71.9M	MT

Summary

The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

With an expected P/E ratio at 46.85 and 42.56 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The valuation of the company is particularly high given the cash flows generated by its activity.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Software

	1st Jan change	Capi.	ESG Refinitiv
HEALTHSTREAM, INC.	-5.25%	778M	C+
ORACLE CORPORATION	+11.17%	322B	B-
SAP SE	+24.75%	216B	B+
SERVICENOW, INC.	+2.41%	149B	B
CONSTELLATION SOFTWARE INC.	+10.65%	56.27B	D+
HUBSPOT, INC.	+8.71%	32.13B	B+
FAIR ISAAC CORPORATION	-4.57%	27.45B	C+
MICROSTRATEGY INCORPORATED	+103.03%	22.62B	D+
WISETECH GLOBAL LIMITED	+20.22%	19.55B	B-
TRIMBLE, INC.	+13.06%	14.69B	B

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes